CA-BETTERWORKS
14.3.2024 10:01:27 CET | Business Wire | Press release
Leading performance management software company Betterworks will debut the executive summary of its highly anticipated 2024 State of Performance Enablement Research Report at its upcoming EmpowerHR Europe virtual summit. The dynamic virtual event, designed for European senior HR professionals and their teams, including HRIT, will take place on 21 March from 9 a.m. to 2 p.m. GMT.
Emceed by Hung Lee, the EmpowerHR Virtual Summit promises to be a high-energy, half-day event packed with insights, strategies, and tools aimed at driving transformative change, elevating HR functions, and enhancing careers. You can register here.
“EmpowerHR will showcase an impressive line-up of speakers immersed in transformative practices to share their expert guidance and insights as the workplace continues to evolve and AI reshapes the world of work,” said Jamie Aitken, VP of HR Transformation at Betterworks. “We’re so excited to bring our community together to learn, network, and explore strategies to lead their organizations as they navigate this dynamic landscape.”
Aitken will kick off the event by sharing significant findings from the State of Performance Enablement report, including the major gaps in perceptions of performance management between HR and leadership and managers and individual contributors. The data demonstrates that combining an HCM with a purpose-built solution leads to much better outcomes than only using an HCM – which can be no different or even worse than solely using manual processes.
Additionally, the report details critical issues facing HR leaders in performance management, equipping leaders with recommendations and insights to take action and improve employee experience and performance at their organization.
Additional EmpowerHR Europe highlights include:
- Keynote presentations by renowned experts and authors Katie King and Tim Ringo: King will share inspiring examples of how HR teams are leveraging AI to transform every aspect of their HR; Ringo will dive into how technology can make managers, HR, and employees exponentially more effective.
- Aitken will lead a fireside chat on revolutionizing HR in the age of AI, offering insights into how HR professionals can best adapt in this evolving landscape to find and maintain a competitive edge for their organizations and in their personal careers.
- HR practitioners from companies including HelloFresh, Ferrer, and Wolt will share their real-world strategies for driving transformation within their organizations and leveraging technology to enhance HR processes and drive efficiency.
Throughout the EmpowerHR Virtual Summit, HR professionals will learn about positioning themselves as strategic partners in their organizations, aligning HR initiatives with business objectives, and employing generative AI and data analytics to improve and accelerate decision-making around workforce planning, talent acquisition, intelligent performance management, and employee engagement.
Register and gain access to the event here.
About Betterworks
Founded in 2013, Betterworks is the pioneer in intelligent performance management solutions that help workforces and organizations achieve their highest potential. Betterworks reimagines performance management for all with an enterprise-ready platform that fosters greater manager effectiveness and employee performance, leading to higher satisfaction and retention and better business outcomes. It combines generative AI and data analytics that enable organizations to make smart, data-based decisions with a comprehensive solution that incorporates conversations, check-ins, feedback, employee engagement, and recognition — all accessible in the applications employees use daily.
Our customers’ employees are proven more engaged and satisfied in their roles, which is why industry leaders like Colgate-Palmolive, Intuit, Udemy, Freddie Mac, Kroger, Vertiv, and the University of Phoenix rely on Betterworks to manage and enable excellent performance. Betterworks is backed by Kleiner Perkins, Emergence Capital, and John Doerr.
For more information, please visit www.betterworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314890936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom